Merck & Co., Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Merck & Co., Inc. (MRK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $18.61 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-24
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $7.83, a 0.76% decline year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-03-31 was $7.89, a 36.98% increase year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-03-31 was $5.76, a 17.48% decline year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-03-31 was $6.98, a 13.83% decline year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $18.61, a 27.30% decline from fiscal 2024.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $25.60, a 18.03% increase from fiscal 2023.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $21.69, a 40.39% increase from fiscal 2022.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $15.45, a 57.65% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $18.61 10-K · filed 2026-02-24 | |||||
| 2024-12-31 | $25.60 10-K · filed 2026-02-24 | |||||
| 2023-12-31 | $21.69 10-K · filed 2026-02-24 | |||||
| 2022-12-31 | $15.45 10-K · filed 2025-02-25 | |||||
| 2021-12-31 | $9.80 10-K · filed 2024-02-26 | |||||
| 2020-12-31 | $9.93 10-K · filed 2023-02-24 | |||||
| 2020-09-30 | $9.93 10-Q · filed 2020-11-05 | |||||
| 2020-06-30 | $9.93 10-Q · filed 2020-08-05 | |||||
| 2019-12-31 | $10.63 10-K · filed 2022-02-25 | |||||
| 2019-09-30 | $10.63 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $10.63 10-Q · filed 2020-08-05 | |||||
| 2018-12-31 | $8.26 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $8.19 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | $8.19 10-Q · filed 2019-08-06 | |||||
| 2018-03-31 | $7.83 10-Q · filed 2019-05-08 | |||||
| 2017-12-31 | $7.04 10-K · filed 2020-02-26 | |||||
| 2017-09-30 | $7.04 10-Q · filed 2018-11-06 | |||||
| 2017-06-30 | $7.05 10-Q · filed 2018-08-07 | |||||
| 2017-03-31 | $7.89 10-Q · filed 2018-05-08 | |||||
| 2016-12-31 | $5.89 10-K · filed 2019-02-27 | |||||
| 2016-09-30 | $5.89 10-Q · filed 2017-11-07 | |||||
| 2016-06-30 | $5.89 10-Q · filed 2017-08-08 | |||||
| 2016-03-31 | $5.76 10-Q · filed 2017-05-09 | |||||
| 2015-12-31 | $6.46 10-K · filed 2018-02-27 | |||||
| 2015-09-30 | $6.46 10-Q · filed 2016-11-07 | |||||
| 2015-06-30 | $6.47 10-Q · filed 2016-08-08 | |||||
| 2015-03-31 | $6.98 10-Q · filed 2016-05-09 | |||||
| 2014-12-31 | $6.79 10-K · filed 2017-02-28 | |||||
| 2014-09-30 | $6.79 10-Q · filed 2015-11-05 | |||||
| 2014-06-30 | $6.79 10-Q · filed 2015-08-06 | |||||
| 2014-03-31 | $8.10 10-Q · filed 2015-05-07 | |||||
| 2013-12-31 | $6.21 10-K · filed 2016-02-26 | |||||
| 2013-09-30 | $6.21 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | $6.21 10-Q · filed 2014-08-07 | |||||
| 2012-12-31 | $5.47 10-K · filed 2015-02-27 | |||||
| 2012-09-30 | $5.47 10-Q · filed 2013-11-07 | |||||
| 2012-06-30 | $5.46 10-Q · filed 2013-08-07 | |||||
| 2012-03-31 | $5.17 10-Q · filed 2013-05-09 | |||||
| 2011-12-31 | $5.39 10-K · filed 2014-02-27 | |||||
| 2011-09-30 | $5.37 10-Q · filed 2012-11-09 | |||||
| 2011-06-30 | $5.37 10-Q · filed 2012-08-07 | |||||
| 2011-03-31 | $5.96 10-Q · filed 2012-05-08 | |||||
| 2010-12-31 | $7.99 10-K · filed 2013-02-28 | |||||
| 2010-09-30 | $7.99 10-Q · filed 2011-11-08 | $34.27 10-Q · filed 2010-11-08 | ||||
| 2010-06-30 | $8.02 10-Q · filed 2011-08-08 | $34.25 10-Q · filed 2010-08-06 | ||||
| 2010-03-31 | $6.68 10-Q · filed 2011-05-09 | |||||
| 2009-12-31 | $4.02 10-K · filed 2012-02-28 | |||||
| 2009-09-30 | $23.95 10-Q · filed 2010-11-08 | |||||
| 2009-06-30 | $23.76 10-Q · filed 2010-08-06 | |||||
| 2008-12-31 | $9.80 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |